The Uprising Role of Histone Deacetylase Inhibitors in Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 August 2024) | Viewed by 1982

Special Issue Editors


E-Mail Website
Guest Editor
Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece
Interests: surgery; transplantation; surgical oncology; oncology; experimental surgery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 15772 Athens, Greece
Interests: surgery; hepatocellular carcinoma; targeted therapies

Special Issue Information

Dear Colleagues,

Histone modification, which occurs through the process of acetylation, plays a key role in the epigenetic regulation of gene expression. The balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT) controls this process. HDAC inhibitors (HDACI) can induce cancer cell cycle arrest, differentiation, and cell death, reduce angiogenesis, and modulate immune response. Therefore, HDACI represent a group of enzymes that can be used for the development of pharmaceutical agents against a variety of malignant neoplastic diseases. Mechanisms of HDACI anticancer effect depends on many factors. HDACIs vorinostat, romidepsin, and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDACI are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising, but further larger studies are needed.

Dr. Christos Damaskos
Dr. Nikolaos Garmpis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • histone
  • acetylation
  • deacetylation
  • inhibitor
  • cancer
  • targeted
  • therapy
  • epigenetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 2151 KiB  
Article
Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
by Christos Damaskos, Iason Psilopatis, Anna Garmpi, Dimitrios Dimitroulis, Konstantinos Nikolettos, Kleio Vrettou, Panagiotis Sarantis, Evangelos Koustas, Gregory Kouraklis, Efstathios A. Antoniou, Michail V. Karamouzis, Nikolaos Nikolettos, Panagiotis Tsikouras, Georgios Marinos, Emmanouil Kontomanolis, Konstantinos Kontzoglou and Nikolaos Garmpis
Cancers 2024, 16(1), 209; https://doi.org/10.3390/cancers16010209 - 1 Jan 2024
Cited by 1 | Viewed by 1660
Abstract
Background/Aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of [...] Read more.
Background/Aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. Materials and Methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients. Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer. Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence. Full article
(This article belongs to the Special Issue The Uprising Role of Histone Deacetylase Inhibitors in Cancer Therapy)
Show Figures

Figure 1

Back to TopTop